750 related articles for article (PubMed ID: 27611861)
1. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
3. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
[TBL] [Abstract][Full Text] [Related]
4. The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy.
Oh KS; Lee JH; Yi KY; Lim CJ; Lee S; Park CH; Seo HW; Lee BH
Br J Pharmacol; 2015 May; 172(10):2618-33. PubMed ID: 25597918
[TBL] [Abstract][Full Text] [Related]
5. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
[TBL] [Abstract][Full Text] [Related]
6. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
[TBL] [Abstract][Full Text] [Related]
7. Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.
Bruce E; Shenoy V; Rathinasabapathy A; Espejo A; Horowitz A; Oswalt A; Francis J; Nair A; Unger T; Raizada MK; Steckelings UM; Sumners C; Katovich MJ
Br J Pharmacol; 2015 May; 172(9):2219-31. PubMed ID: 25522140
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-κB activation.
Shi W; Zhai C; Feng W; Wang J; Zhu Y; Li S; Wang Q; Zhang Q; Yan X; Chai L; Liu P; Chen Y; Li M
Life Sci; 2018 Oct; 210():140-149. PubMed ID: 30179628
[TBL] [Abstract][Full Text] [Related]
9. Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway.
Gao H; Cheng Y; Zong L; Huang L; Qiao C; Li W; Gong B; Hu J; Liu H; Wang X; Zhao C
Clin Exp Hypertens; 2017; 39(1):34-41. PubMed ID: 28055284
[TBL] [Abstract][Full Text] [Related]
10. Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-κB Signaling Pathway to Attenuate Vascular Remodeling.
Liu J; Fang G; Lan C; Qiu C; Yao L; Zhang Q; Hu J; Zhang Y; Yang Y; Zhang Y
Drug Des Devel Ther; 2024; 18():767-780. PubMed ID: 38495631
[TBL] [Abstract][Full Text] [Related]
11. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
12. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
[TBL] [Abstract][Full Text] [Related]
13. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
Zhu N; Zhao X; Xiang Y; Ye S; Huang J; Hu W; Lv L; Zeng C
Int J Cardiol; 2016 Oct; 221():587-96. PubMed ID: 27420584
[TBL] [Abstract][Full Text] [Related]
14. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Zheng Y; Ma H; Hu E; Huang Z; Cheng X; Xiong C
J Cardiovasc Pharmacol; 2015 Nov; 66(5):504-14. PubMed ID: 26535780
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice.
Li L; Wei C; Kim IK; Janssen-Heininger Y; Gupta S
Hypertension; 2014 Jun; 63(6):1260-9. PubMed ID: 24614212
[TBL] [Abstract][Full Text] [Related]
17. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
18. Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response.
Yang JM; Zhou R; Zhang M; Tan HR; Yu JQ
Molecules; 2018 May; 23(6):. PubMed ID: 29861433
[TBL] [Abstract][Full Text] [Related]
19. Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.
Chen YC; Yuan TY; Zhang HF; Wang DS; Yan Y; Niu ZR; Lin YH; Fang LH; Du GH
Acta Pharmacol Sin; 2016 Jun; 37(6):772-82. PubMed ID: 27180980
[TBL] [Abstract][Full Text] [Related]
20. Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects.
Beik A; Najafipour H; Joukar S; Rajabi S; Iranpour M; Kordestani Z
Clin Exp Hypertens; 2021 Apr; 43(3):270-280. PubMed ID: 33322932
[No Abstract] [Full Text] [Related]
[Next] [New Search]
